Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

23 May 2011

Abstract excerpt

The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins and thereby regulates protein levels within the cell. Given this important role in maintaining cellular homeostasis, it is perhaps somewhat surprising that proteasome inhibitors have a therapeutic window. Proteasome inhibitors have demonstrated clinical efficacy in the treatment of multiple myeloma and mantle cell lymphoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21606441
DOI: 10.1093/jnci/djr160

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Proteasome Inhibitors to Overcome Bortezomib ResistancePMID 21606441Read ↗

The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disordersSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

Molecular Mechanisms of Acquired Proteasome Inhibitor ResistanceSemantic proximity Read ↗

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Protein degradation: expanding the toolbox to restrain cancer drug resistanceSemantic proximity Read ↗

Emerging therapies targeting the ubiquitin proteasome system in cancerSemantic proximity Read ↗

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.Semantic proximity Read ↗

Proteasome as an Emerging Therapeutic Target in CancerSemantic proximity Read ↗

The role of proteasomes in tumorigenesisSemantic proximity Read ↗

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Semantic proximity Read ↗

Investigating the mechanisms underlying Bortezomib resistanceSemantic proximity Read ↗

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.